# US Heart Transplant Market > US Heart Transplant Market Research Report: Size, Share, Trend Analysis By Surgery type (Ventricular Assist Devices, Total Artificial hearts, Others) and By End Users (Hospital, Cardiac Institutes, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.1% - **2024:** $ 3,021.09 Million - **2025:** $ 3,326.23 Million - **2035:** $ 8,708.28 Million - **Key Players:** Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cardinal Health (US), Baxter (US), Fresenius (DE), LivaNova (GB), AstraZeneca (GB), Novartis (CH) **Report ID:** MRFR/MED/18401-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-heart-transplant-market-19948 --- ## Market Summary ## **US Heart Transplant Market Overview** As per MRFR analysis, the US Heart Transplant Market Size was estimated at 2.74 (USD Billion) in 2023. The US Heart Transplant Market Industry is expected to grow from 3.5(USD Billion) in 2024 to 9 (USD Billion) by 2035. The US Heart Transplant Market CAGR (growth rate) is expected to be around 8.965% during the forecast period (2025 - 2035). ### **Key US Heart Transplant Market Trends Highlighted** The US Heart Transplant Market is witnessing several important trends that reflect advancements in medical technology and a growing understanding of patient needs. One key market driver is the increasing prevalence of end-stage heart failure, which has prompted more patients to seek heart transplantation as a treatment option. Moreover, the aging population in the US contributes to this trend as older adults often experience cardiac issues that may lead to transplantation. Additionally, the development of innovative surgical techniques and improved post-operative care has enhanced transplant success rates, driving more patients to opt for this life-saving procedure. Opportunities in the US market can be captured through the expansion of donor programs and better allocation of donor hearts. Increased awareness and education regarding organ donation among the general public are crucial. Furthermore, initiatives that streamline the transplant process can lead to quicker patient recovery times and improved quality of life, making heart transplants more appealing to patients and healthcare providers alike. Recent times have also seen a trend toward the utilization of technology in matching donors with recipients more effectively. The use of artificial intelligence and data analytics is helping to optimize allocation processes, ensuring that donor hearts are matched with patients who need them the most urgently. Additionally, patient-centric approaches are gaining traction, with more emphasis on personalized medicine and tailored postoperative support. All these factors combined are transforming the landscape of the heart transplant market in the US, reflecting a proactive approach in addressing heart failure and improving the overall effectiveness of heart transplant procedures. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Heart Transplant Market Drivers** ### **Increase in Prevalence of Heart Diseases** The increasing prevalence of heart diseases in the United States is a significant driver of growth in the US [Heart Transplant Market](../../../reports/heart-transplant-market-1836) Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 697,000 people died from heart disease in 2020, accounting for 1 in every 5 deaths in the nation. This staggering statistic underscores the urgent need for effective treatments, including heart transplants, which is expected to drive market growth as more patients seek life-saving surgeries. Furthermore, the American Heart Association has projected that by 2030, nearly 43.9% of the U.S. population could have some form of cardiovascular disease, creating an expanded patient base requiring transplantation. The increasing number of patients encourages investment in medical procedures, further propelling the US Heart Transplant Market. ### **Advancements in Medical Technology** Technological advancements in surgical procedures and post-operative care are catalysts for growth in the US Heart Transplant Market Industry. Cutting-edge techniques, such as minimally invasive surgery and improved immunosuppressive therapies, have significantly improved transplant success rates. A report by the Organ Procurement and Transplantation Network indicates that the one-year survival rate for heart transplant recipients improved from around 86% in 1990 to approximately 90% in recent years. This advancement in technology is directly linked to major organizations such as the National Institutes of Health, which allocates substantial funding for Research and Development to enhance transplantation techniques. As these technologies continue to evolve, patient outcomes will improve, attracting more individuals who may benefit from heart transplants. ### **Increased Awareness and Educational Campaigns** Efforts to raise awareness about the benefits of organ donation are contributing to the growth of the US Heart Transplant Market Industry. Campaigns led by organizations like Donate Life America have resulted in increased registration of organ donors. For instance, the National Donate Life Registry reported that as of January 2022, there were over 175 million registered organ donors in the United States, an increase of over 10% compared to previous years. This heightened awareness not only leads to more available organs for transplantation but also encourages potential heart transplant recipients to seek evaluation and treatments. The more people are educated about the importance of organ donation, the more successful the US Heart Transplant Market will become, supporting its upward trajectory. ### **Support from Government Policies and Funding** Government support through policies and funding for organ transplantation is integral to the expansion of the US Heart Transplant Market Industry. Federal initiatives, such as the Organ Transplantation Reform Act, have laid the groundwork for a structured approach toward improving organ donation systems and transplantation processes. As of 2022, the U.S. Department of Health and Human Services increased its funding for organ transplantation programs by 5%, directly impacting the availability of resources for transplant centers across the country. This support not only increases the operational capabilities of these centers but also enhances patient care, leading to better transplant outcomes. Ultimately, government intervention creates a more favorable market environment, contributing to steady growth in the US Heart Transplant Market. ## **US Heart Transplant Market Segment Insights** ### **Heart Transplant Market Surgery type Insights** The US Heart Transplant Market has shown significant growth, particularly highlighted by its segmentation based on surgery type, which plays a crucial role in the treatment of advanced heart failure. In recent years, the demand for advanced surgical methods, such as Ventricular Assist Devices (VADs) and Total Artificial Hearts (TAHs), has become increasingly relevant, given the rising prevalence of heart diseases across the United States. This is driven by various factors, including an aging population, lifestyle choices leading to cardiac ailments, and an increase in the number of patients awaiting transplants. The use of VADs has become a pivotal option for patients, serving as both a bridge to heart transplantation and a destination therapy, thereby enhancing patient longevity and quality of life. TAHs offer a complete solution, particularly for patients who are not candidates for heart transplants, contributing significantly to improving mortality rates in severe heart failure cases. Furthermore, the growing trends in technology and innovation within the US healthcare sector have configured these surgical types to be more efficient, with better outcomes and fewer complications, which is vital for both surgeons and patients. Additionally, the Other category, which encompasses various supportive and related surgeries, provides an essential platform for customized patient care. The synergy between various procedures and devices not only fills the gaps in traditional heart management techniques but also reflects the evolving capabilities within the US Heart Transplant Market industry to adapt to patient needs and technological advancements. Overall, the exploration of surgery types within this market reveals pivotal insights about how advanced surgical options are reshaping treatment paradigms and addressing the significant gap in heart transplant availability and patient care throughout the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Heart Transplant Market End User Insights** The End User segment of the US Heart Transplant Market comprises various critical entities such as hospitals, cardiac institutes, and other medical facilities, each playing a pivotal role in the heart transplant process. Hospitals act as primary caregivers, providing a wide range of treatments and resources, including surgical interventions and post-operative care, essential for patient recovery and monitoring. Cardiac institutes specialize in heart-related conditions and offer advanced research, treatment protocols, and educational support, thus significantly contributing to the overall efficacy of heart transplant procedures. The 'Others' category may include outpatient surgery centers and rehabilitation facilities that play supportive roles in patient pre-and post-transplant care. This segmentation reveals the interdependence of different healthcare facilities in enhancing patient outcomes and underscores the collaborative nature of cardiac care in the US. The growing prevalence of heart diseases and the increasing demand for transplant surgeries further emphasize the importance of these facilities in the US Heart Transplant Market, driving advancements in techniques and technologies for better surgical results. As healthcare systems continue to evolve, these End Users are crucial in adapting to new trends and addressing emerging challenges within the industry. ## **US Heart Transplant Market Key Players and Competitive Insights** The US Heart Transplant Market is an evolving landscape characterized by a growing demand for transplantable organs, advanced surgical techniques, and innovative therapies that enhance transplant success. Within this market, several players are vying for a position of leadership, driven by increased investments in research and development, the emergence of cutting-edge medical technologies, and a supportive regulatory environment. The competitive insights reveal a diverse mix of established companies and newer entrants that are focused on providing comprehensive solutions for heart transplant procedures and post-transplant care. These companies compete not only based on the efficacy of their products and services but also on factors such as patient outcomes, cost-effectiveness, and their ability to navigate the complex healthcare ecosystem. Organogenesis stands as a notable player in the US Heart Transplant Market, recognized for its innovative approaches to tissue regeneration and wound healing. The company has developed a strong portfolio of advanced biological products that support the recovery and rehabilitation of transplant patients. One of its key strengths is its commitment to research, leading to the continual enhancement of its product offerings, which cater to the specific needs of heart transplant recipients. Furthermore, its effective collaborations with clinical partners and robust distribution networks have cemented its position within the market, ensuring that their solutions are accessible across various healthcare settings in the US. Organogenesis has also focused on educating healthcare professionals about the importance of regenerative medicine, thereby increasing awareness and adoption of its technologies in the field of heart transplantation. Asahi Kasei is another significant entity within the US Heart Transplant Market, known for its comprehensive range of medical products and services that facilitate heart surgeries and post-operative care. The company specializes in advanced biomedical materials and has established a solid presence through its innovative offerings, including devices used during transplantation procedures and biocompatible materials for cardiac applications. One of Asahi Kasei's strengths lies in its strong R&D capabilities, which have led to numerous technological advancements that improve patient outcomes. The firm has also pursued strategic mergers and acquisitions to expand its product portfolio and enhance its market footprint in the US. By integrating various technologies and strengthening their supply chain, Asahi Kasei has successfully positioned itself to meet the growing needs of the heart transplant community, showcasing its commitment to improving the quality of life for patients undergoing cardiac procedures. ### **Key Companies in the US Heart Transplant Market Include** ### **US Heart Transplant Market Industry Developments** The US Heart Transplant Market has seen significant developments in recent months, particularly with advancements in organ preservation and the use of innovative technologies. Companies like TransMedics are making strides with their Organ Care System, which enhances the viability of donor hearts, thereby improving transplant outcomes. Meanwhile, Medtronic and Abbott Laboratories are focusing on devices that support heart function, such as ventricular assist devices and total artificial hearts, which play a critical role in managing patients awaiting transplants. In terms of mergers and acquisitions, Astellas Pharma announced the acquisition of a US-based biotech focused on immunology in September 2023, highlighting the increasing interest in novel therapies for transplant rejection. Additionally, Boston Scientific is exploring strategic partnerships to enhance its cardiac interventions portfolio. Over the past two to three years, the US Heart Transplant Market has experienced notable growth, with an increase in transplant surgeries attributed to expanded donor criteria and technological improvements that have broadened donor heart availability. As of early 2023, over 4,000 heart transplants were performed in the US, reflecting a steady upward trend in procedures and patient outcomes in the heart transplant sector. ## **US Heart Transplant Market Segmentation Insights** ### **Heart Transplant Market Surgery type Outlook** ### **Heart Transplant Market End User Outlook** ## Market Drivers ### Rising Incidence of Heart Disease The heart transplant market is experiencing growth due to the increasing prevalence of heart disease in the US. According to the CDC, heart disease remains the leading cause of death, accounting for approximately 697,000 deaths annually. This alarming statistic indicates a growing need for heart transplants as a treatment option for patients with severe heart conditions. As the population ages and lifestyle-related factors contribute to cardiovascular issues, the demand for heart transplants is likely to rise. Furthermore, advancements in surgical techniques and post-operative care are enhancing patient outcomes, making heart transplants a more viable option for those suffering from end-stage heart failure. The heart transplant market is thus positioned to expand as healthcare providers seek to address the escalating burden of heart disease. ### Advancements in Post-Transplant Care Advancements in post-transplant care are playing a pivotal role in the heart transplant market. Improved immunosuppressive therapies and personalized medicine approaches are enhancing patient outcomes and reducing the risk of organ rejection. The introduction of new medications and monitoring technologies allows for better management of transplant recipients, leading to longer survival rates and improved quality of life. As a result, the heart transplant market is witnessing a shift towards more comprehensive care models that focus on long-term patient management. This trend not only supports the sustainability of heart transplants but also encourages more patients to consider transplantation as a viable option for treating end-stage heart disease. The ongoing research and development in this area are likely to further bolster the market as healthcare providers strive to optimize post-transplant care. ### Innovations in Transplant Technology Innovations in transplant technology are significantly impacting the heart transplant market. The development of advanced surgical techniques, such as minimally invasive procedures and robotic-assisted surgeries, is improving patient recovery times and outcomes. Additionally, the introduction of new organ preservation methods, such as normothermic perfusion, is extending the viability of donor hearts, thereby increasing the number of successful transplants. The heart transplant market is also witnessing the emergence of artificial hearts and ventricular assist devices, which serve as temporary solutions for patients awaiting transplants. These technological advancements not only enhance the efficiency of heart transplants but also expand the potential donor pool, ultimately contributing to market growth. As these innovations continue to evolve, they are likely to play a crucial role in shaping the future of heart transplantation. ### Growing Support for Organ Donation Initiatives The heart transplant market is benefiting from a growing support for organ donation initiatives across the US. Public awareness campaigns and educational programs are encouraging individuals to register as organ donors, which is essential for increasing the availability of donor hearts. According to the Organ Procurement and Transplantation Network, there are currently over 100,000 individuals waiting for organ transplants, with a significant portion requiring heart transplants. This increasing awareness and support for organ donation are likely to lead to a rise in the number of available organs, thereby positively impacting the heart transplant market. Furthermore, partnerships between healthcare organizations and non-profits are fostering community engagement and promoting the importance of organ donation, which may further enhance the supply of donor hearts in the coming years. ### Increased Investment in Healthcare Infrastructure Increased investment in healthcare infrastructure is contributing to the growth of the heart transplant market. As hospitals and medical centers enhance their facilities and capabilities, they are better equipped to perform complex heart transplant surgeries. This investment includes upgrading surgical suites, expanding transplant programs, and improving patient care services. According to the American Hospital Association, healthcare spending in the US is projected to reach $6.2 trillion by 2028, indicating a strong commitment to improving healthcare delivery. The heart transplant market stands to benefit from this trend, as enhanced infrastructure can lead to more efficient transplant processes and better patient outcomes. Additionally, increased funding for research and development in transplant medicine may yield new therapies and technologies, further driving market growth. ## Future Outlook The [Heart Transplant Market](https://www.marketresearchfuture.com/reports/heart-transplant-market-1836) is projected to grow at a 10.1% CAGR from 2025 to 2035, driven by advancements in surgical techniques, increasing donor availability, and enhanced post-operative care. **New opportunities:** - Development of telehealth platforms for post-transplant monitoring Investment in bioprinting technologies for organ creation Expansion of transplant centers in underserved regions By 2035, the heart transplant market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Ventricular Assisted Device (Largest) vs. Total Artificial Hearts (Fastest-Growing) In the US heart transplant market, the segment values reveal a competitive landscape with Ventricular Assisted Devices (VADs) holding the largest market share. This segment has shown strong performance due to increasing reliance on VADs as a supportive therapy for patients awaiting transplants. In contrast, Total Artificial Hearts represent an emerging segment that is witnessing rapid growth, attributed to advancements in technology and a rising number of patients in need of artificial heart options. Growth trends in the market are predominantly driven by technological innovations, increased awareness of heart diseases, and the ongoing shortage of donor organs. While VADs remain the standard for mechanical support, the growing success rates of Total Artificial Hearts indicate a shift towards more integrated solutions for severe heart failure, potentially transforming patient outcomes and expanding market reach over the coming years. Ventricular Assisted Device (Dominant) vs. Total Artificial Hearts (Emerging) Ventricular Assisted Devices are established as the dominant solution in the US heart transplant market. These devices are widely used in clinical practice to extend the lives of patients with advanced heart failure, bridging them to heart transplants or providing long-term therapy. Their reliability, combined with rigorous clinical backing, contributes to their significant market presence. On the other hand, Total Artificial Hearts are emerging as a viable alternative for end-stage heart failure patients without donor options. The recent advancements in artificial heart technologies have improved their safety and efficacy, making them an attractive option for surgeons and patients alike. As clinical trials continue to show favorable results, the Total Artificial Hearts segment is expected to gain traction in the market, offering renewed hope for individuals facing severe cardiac challenges. ### By End User: Hospitals (Largest) vs. Cardiac Institutes (Fastest-Growing) In the US heart transplant market, the distribution of market share among end users prominently features hospitals as the largest segment. These institutions not only offer advanced surgical capabilities but also have a well-established infrastructure for post-transplant care. Cardiac institutes, while currently smaller in share, are rapidly gaining attention and investment, showcasing a dynamic growth trajectory driven by innovations in cardiac care. The growth of the cardiac institutes segment is propelled by increasing patient awareness and demand for specialized cardiac care. Factors such as advancements in transplant techniques, growing partnerships with hospitals, and enhanced patient outcomes contribute to this trend. Moreover, the emphasis on personalized medicine and improved patient monitoring systems positions cardiac institutes as a pivotal player, indicating a competitive shift within the segment. Hospitals: Core Provider (Dominant) vs. Cardiac Institutes: Specialized Care (Emerging) Hospitals are the core providers in the US heart transplant market, characterized by their extensive resources, experienced staffing, and comprehensive facilities that support both surgical and follow-up care. Their dominant position is fortified by established protocols and routines that ensure patient safety and successful outcomes. In contrast, cardiac institutes represent an emerging force in this landscape, focusing on specialized care that enhances the patient experience and leverages cutting-edge technology. They often cater to a niche audience, addressing specific cardiac conditions with heightened expertise. This specialization enables them to attract a growing patient base, bolstered by collaborations and advancements in cardiac research. ## Competitive Benchmarking The heart transplant market is characterized by a dynamic competitive landscape, driven by advancements in medical technology, increasing patient demand, and a growing emphasis on personalized medicine. Key players such as Abbott (US), Medtronic (US), and Boston Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott (US) focuses on innovation through the development of cutting-edge devices that improve transplant outcomes, while Medtronic (US) emphasizes partnerships with healthcare providers to streamline patient care. Boston Scientific (US) is leveraging digital transformation to enhance patient monitoring and post-operative care, collectively shaping a competitive environment that prioritizes technological advancement and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies consolidate their positions through strategic acquisitions and partnerships, thereby enhancing their operational capabilities and market reach. In October Abbott (US) announced a collaboration with a leading research institution to develop a next-generation heart monitoring device aimed at improving post-transplant patient outcomes. This strategic move underscores Abbott's commitment to innovation and positions the company to capitalize on the growing demand for advanced monitoring solutions in the transplant space. The partnership is expected to accelerate the development timeline and enhance Abbott's competitive edge. In September Medtronic (US) launched a new initiative focused on integrating artificial intelligence (AI) into their heart transplant management systems. This initiative aims to optimize patient selection and post-operative care, potentially reducing complications and improving overall survival rates. By harnessing AI, Medtronic (US) is likely to enhance its operational efficiency and provide more personalized care, which could significantly impact patient outcomes in the long term. In August Boston Scientific (US) expanded its product portfolio by acquiring a startup specializing in telehealth solutions for transplant patients. This acquisition reflects Boston Scientific's strategy to integrate digital health technologies into its offerings, thereby enhancing patient engagement and monitoring. The move is indicative of a broader trend towards digitalization in the healthcare sector, which is becoming increasingly vital in managing complex transplant cases. As of November current trends in the heart transplant market indicate a shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the need for collaboration to drive innovation and improve patient outcomes. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized patient care. This shift may redefine the competitive landscape, emphasizing the importance of adaptability and forward-thinking strategies. ## Recent News & Developments The US Heart Transplant Market has seen significant developments in recent months, particularly with advancements in organ preservation and the use of innovative technologies. Companies like TransMedics are making strides with their Organ Care System, which enhances the viability of donor hearts, thereby improving transplant outcomes. Meanwhile, Medtronic and Abbott Laboratories are focusing on devices that support heart function, such as ventricular assist devices and total artificial hearts, which play a critical role in managing patients awaiting transplants. In terms of mergers and acquisitions, Astellas Pharma announced the acquisition of a US-based biotech focused on immunology in September 2023, highlighting the increasing interest in novel therapies for transplant rejection. Additionally, Boston Scientific is exploring strategic partnerships to enhance its cardiac interventions portfolio. Over the past two to three years, the US Heart Transplant Market has experienced notable growth, with an increase in transplant surgeries attributed to expanded donor criteria and technological improvements that have broadened donor heart availability. As of early 2023, over 4,000 heart transplants were performed in the US, reflecting a steady upward trend in procedures and patient outcomes in the heart transplant sector. ## Report Scope | MARKET SIZE 2024 | 3021.09(USD Million) | | --- | --- | | MARKET SIZE 2025 | 3326.23(USD Million) | | MARKET SIZE 2035 | 8708.28(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.1% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cardinal Health (US), Baxter (US), Fresenius (DE), LivaNova (GB), AstraZeneca (GB), Novartis (CH) | | Segments Covered | Type, End User | | Key Market Opportunities | Advancements in organ preservation techniques enhance viability and expand donor heart availability in the heart transplant market. | | Key Market Dynamics | Technological advancements and regulatory changes are reshaping the competitive landscape of the heart transplant market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US heart transplant market in 2024?** A: The overall market valuation was $3021.09 Million in 2024. **Q: What is the projected market valuation for the US heart transplant market by 2035?** A: The projected valuation for 2035 is $8708.28 Million. **Q: What is the expected CAGR for the US heart transplant market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 10.1%. **Q: Which companies are considered key players in the US heart transplant market?** A: Key players include Abbott, Medtronic, Boston Scientific, Terumo, Cardinal Health, Baxter, Fresenius, LivaNova, AstraZeneca, and Novartis. **Q: What are the main segments of the US heart transplant market?** A: The main segments include Ventricular Assisted Devices, Total Artificial Hearts, and Others. **Q: What was the market size for Ventricular Assisted Devices in 2024?** A: The market size for Ventricular Assisted Devices was $1200.0 Million in 2024. **Q: What is the projected market size for Total Artificial Hearts by 2035?** A: The projected market size for Total Artificial Hearts by 2035 is $2500.0 Million. **Q: How do hospitals and cardiac institutes compare in terms of market size in 2024?** A: In 2024, hospitals had a market size of $1200.0 Million, while cardiac institutes had $1500.0 Million. **Q: What is the expected growth trend for the 'Others' segment in the US heart transplant market?** A: The 'Others' segment is expected to grow from $1021.09 Million in 2024 to $3708.28 Million by 2035. **Q: What role do key players like Medtronic and Abbott play in the market's growth?** A: Companies like Medtronic and Abbott are likely to drive innovation and market expansion, contributing to the projected growth. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-heart-transplant-market-19948*